Lexicon Pharmaceuticals, Inc.
LXRX
$1.62
$0.010.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -79.31% | 710.40% | 1,652.64% | 11.68% | 3,682.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -79.31% | 710.40% | 1,652.64% | 11.68% | 3,682.62% |
| Cost of Revenue | 16.07% | -27.40% | -10.41% | -1.29% | -447.95% |
| Gross Profit | -37.55% | 80.98% | 13,843.94% | 30.91% | 653.16% |
| SG&A Expenses | -72.85% | -80.80% | -76.14% | -63.79% | 3.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -65.16% | -59.71% | -55.91% | -42.02% | 26.50% |
| Operating Income | 53.28% | 80.87% | 106.75% | 43.35% | 30.16% |
| Income Before Tax | 54.01% | 80.30% | 106.09% | 47.73% | 32.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.01% | 80.30% | 106.09% | 47.73% | 32.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.01% | 80.30% | 106.09% | 47.73% | 32.14% |
| EBIT | 53.28% | 80.87% | 106.75% | 43.35% | 30.16% |
| EBITDA | 53.47% | 81.07% | 107.09% | 43.56% | 30.21% |
| EPS Basic | 54.28% | 80.42% | 105.24% | 64.55% | 54.01% |
| Normalized Basic EPS | 52.74% | 80.37% | 105.21% | 64.56% | 54.18% |
| EPS Diluted | 54.28% | 80.42% | 105.24% | 64.55% | 54.01% |
| Normalized Diluted EPS | 52.74% | 80.37% | 105.21% | 64.56% | 54.18% |
| Average Basic Shares Outstanding | 0.54% | 0.53% | 16.88% | 47.55% | 47.59% |
| Average Diluted Shares Outstanding | 0.54% | 0.53% | 16.97% | 47.55% | 47.59% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |